Investigational Drug Information for BIIB074
What is the development status for investigational drug BIIB074?
BIIB074 is an investigational drug.
There have been 18 clinical trials for BIIB074.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 19th 2023.
The most common disease conditions in clinical trials are Neuralgia, Trigeminal Neuralgia, and Bipolar Disorder. The leading clinical trial sponsors are Biogen, GlaxoSmithKline, and Convergence Pharmaceuticals.
There are seventy-eight US patents protecting this investigational drug and four hundred and eighteen international patents.
Summary for BIIB074
| US Patents | 78 |
| International Patents | 418 |
| US Patent Applications | 185 |
| WIPO Patent Applications | 70 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 2 (2023-04-19) |
| Vendors | 40 |
Recent Clinical Trials for BIIB074
| Title | Sponsor | Phase |
|---|---|---|
| 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Biogen | Phase 3 |
| 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia | Biogen | Phase 3 |
| Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy | Biogen | Phase 1 |
Clinical Trial Summary for BIIB074
Top disease conditions for BIIB074
Top clinical trial sponsors for BIIB074
US Patents for BIIB074
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BIIB074 | ⤷ Start Trial | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (Boston, MA) | ⤷ Start Trial |
| BIIB074 | ⤷ Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Start Trial |
| BIIB074 | ⤷ Start Trial | Methods and compositions for decreasing gastric emptying | Purdue Pharma L.P. (Stamford, CT) | ⤷ Start Trial |
| BIIB074 | ⤷ Start Trial | Erythromelalgia treatment | Convergence Pharmaceuticals Limited (Maidenhead, GB) | ⤷ Start Trial |
| BIIB074 | ⤷ Start Trial | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (Boston, MA) | ⤷ Start Trial |
| BIIB074 | ⤷ Start Trial | Process for preparing alpha-carboxamide pyrrolidine derivatives | Convergence Pharmaceuticals Limited (GB) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BIIB074
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BIIB074 | Argentina | AR094667 | 2033-01-31 | ⤷ Start Trial |
| BIIB074 | Australia | AU2014212509 | 2033-01-31 | ⤷ Start Trial |
| BIIB074 | Australia | AU2018214105 | 2033-01-31 | ⤷ Start Trial |
| BIIB074 | Australia | AU2020204425 | 2033-01-31 | ⤷ Start Trial |
| BIIB074 | Brazil | BR112015018289 | 2033-01-31 | ⤷ Start Trial |
| BIIB074 | Canada | CA2898866 | 2033-01-31 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
